Combined Transarterial Chemoembolization and Percutaneous Radiofrequency Ablation: More Promising Evidence of Effectiveness in Treating Solitary, Medium-Sized Hepatocellular Carcinoma
Locoregional therapy (LRT) has become a cornerstone in the management of patients with surgically unresectable hepatocellular carcinoma (HCC). Transarterial chemoembolization and percutaneous radiofrequency (RF) ablation —both prototypical LRTs with long track records of use—prolong overall survival (OS) in HCC patients (1–3) but have shortcomings when used independently (4). Although transarterial chemoembolization is the current standard of care for patients with Barcelona Clinic Liver Cancer stage B (interm ediate-stage) HCC, it is considered a palliative treatment rather than a curative treatment.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Ketan Y. Shah, Ron C. Gaba Tags: Commentary Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Palliative | Radiology | Urology & Nephrology